When you absolutely have to recruit patients on time
A DECADE OF SERVICE
Accell is established as a clinical CRO providing Phase I – IV clinical study management services. The company serves as a reliable partner in completing clinical studies on time, and the first three Phase II oncology studies are initiated.
Accell begins working in Europe on the first project with breast cancer patients, covering Sweden, Germany, France, Baltic countries, Russia and Ukraine.
To provide regulatory services, Accell establishes a regional clinical office in Kiev, Ukraine. Our clients gain reliable access to a largely untapped patient population with the Accell's rigorous quality management practices applied.
Located near Charlottesville, VA, with easy access to Washington, D.C., Northern Virginia and Maryland, our Virginia office serves as a strong anchor for the outreach to East Coast biopharmaceutical industry.
Accell open a regional clinical office in Riga, Latvia to meet the demand for regulatory and pharmacovigilance services in the European Union. An Latvian office facilitates regulatory reporting in the European Union.
HANDS-ON FOUNDERS: A DIFFERENT LEVEL OF SUPPORT AND CONFIDENCE
Our journey started when working side-by-side on clinical studies we realized the tremendous financial waste created by study delays. All of the studies we worked on together had one thing in common: they could absolutely take no risk of running behind schedule. We saw first-hand that in our region the patients frequently received better care and treatment access within the clinical trial. This was hope for the cure for many.
We knew we could promise both, our clients and the patients, better outcomes. So, we put together our heads, hands and hearts, and Accell Clinical Research was born. – Natalia Nayanova & Julia Kondakov, Founders
GLOBAL CHALLENGES IN CLINICAL TRIALS
80% of all clinical trials fall behind schedule due to patient recruitment. 50% of sites enroll only 1 patient
Nearly one-third of sites performing clinical trials never enroll a single patient
Almost $2B spent on underperforming sites in 4 years by global pharma community
Protocol complexity increases are proportional to enrollment rate decreases
THE ACCELL DIFFERENCE: A STRONG OPERATIONAL STRATEGY
As protocol complexity increases, the patient enrollment rates decrease almost proportionately, as studies show. While we recognize and meet the need for more robust, complex treatment protocols, we never lose sight of our goal: to complete enrollment on time.
At Accell we develop a strong operational strategy and patient recruitment and retention approach individually for each study. Our strategic focus is accurate country selection, and on working with academic or national hospitals, or hospitals supported by extensive satellite networks. We believe in building knowledge and relationships: from 2015 to 2017 we worked with over 700 investigators in various therapeutic areas.
Our Mission Remains Simple:
WE GIVE HOPE TO THE PATIENTS.
WE ARE IN EQUAL PARTS GUIDING AND FLEXIBLE
Our dedicated and loyal clinical team consisting of mostly physicians is devoted to navigating clients through each step, from planning to execution of the clinical study. This requires both global and academic thinking, and excellent knowledge of local regulations and healthcare institutions. Yet, we can relate and adapt to the unique challenges of each study and specific client needs.